期刊文献+

苯并环庚并吡啶类法呢基蛋白转移酶抑制剂的三维定量构效关系的研究

THREE DIMENSIONAL QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP OF A SERIES OF BENZOCYLOHEPTAPYRIDINE FARNESYLTRANSFERASE INHIBITORS
暂未订购
导出
摘要 目的 建立苯并环庚并吡啶类法呢基蛋白转移酶 (FPTase)抑制剂三维定量构效关系模型。方法和结果利用比较分子力场分析方法对 69个苯并环庚并吡啶类FPTase抑制剂建立了三维定量构效模型 ,模型的交叉验证系数R2 =0 5 81,非交叉验证系数R2 =0 968,SE =0 14 8,F =198 7。结论 利用所获得CoMFA模型对 10个FPTase抑制剂进行了活性预测 ,预测值与实测值相近 ,说明利用该模型进行新苯并环庚并吡啶类FPTase抑制剂分子设计有较好的可信度。 AIM To build a three dimensional structure model that correlates the biological activities and the structures of a series of 1 (8 chloro 6,11 dihydro 5H benzo[5,6]cyclohepta [1,2 ]pyridin 11 yl)piperazines farnesyl protein transferase (FPTase) inhibitors. METHODS AND RESULTS Mutation in the ras oncogene takes place in many human cancers, involving 30%~50% of colon and 90% of pancreatic cancer. Ras proteins function as central switches for signals given by growth factors that direct cell growth and cell differentiation. The dependence of the transforming activity of Ras on the farnesylation has led to an intense search for FPTase inhibitors that may have therapeutic pontetial as anticancer agents. This paper is to build a three dimensional structural model that correlates the biological activities and the structures of a series of FPTase inhibitors. The investigated sixty nine inhibitors contain six types of structures, the optimal conformations of which were studied using system search. A three dimensional quantitative structure activity relationship (3D QSAR) model was constructed using the method of comparative molecular field analysis (CoMFA). The resulting cross validiation R 2 is 0 581, non cross validiation R 2 0 968, SE 0 148, F 198 7. The predicted activities of 10 inhibitors using this 3D QSAR model are comparable to the experimental activities, indicating that the 3D QSAR model has ability to predict activities of new inhibitors and offers an approach to design new FPTase inhibitors. CONCLUSION The information of CoMFA model offers an approach to designing new FPTase inhibitors.
机构地区 中国医学科学院
出处 《药学学报》 CAS CSCD 北大核心 2002年第4期257-262,共6页 Acta Pharmaceutica Sinica
基金 国家重点基础研究发展规划 973项目 (G19980 5 110 2 ) .
关键词 法呢基蛋白转移酶 FPTase 比较分子场分析 COMFA 吡啶并苯 环庚烯 抗癌药 Farnesyl protein transferase (FPTase) comparative molecular field analysis (CoMFA) benzocycloheptapyridine
  • 相关文献

参考文献16

  • 1Casey PJ, Solski PA, Der CJ, et al. P21 ras is modified by a farnesyl isoprenoid. Proc Natl Acad Sci USA [J], 1989,86(21):8323-8327.
  • 2Hancock JF, Magee AI, Chilad JE, et al. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell [J], 1989,57(7):1167-1177.
  • 3Schafer WR, Kim R, Sterne R, et al. Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and humans. Science [J], 1989,245(4916):379-385.
  • 4Ashby MN, King DS, Rine J. Endoproteolytic processing of a farnesylated peptide in vitro. Proc Natl Acad Sci USA [J], 1992,89(10):4613-4617.
  • 5Ma YT, Rando RR. A microsomal endoprotease that specifically cleaves isoprenylated peptides. Proc Natl Acad Sci USA [J], 1992,89(13):6275-6279.
  • 6Boyartchuk VL, Rine J. Roles of prenyl proteins in muturation of sccharomyces cerevisiae α-factor. Genetics [J], 1998,150(1):95-101.
  • 7Otto JC, Kim E, Yong SG, et al. Cloning and characterization of a mammalian prenyl protein specific protease. J Biol Chem [J], 1999,274(13):8379-8382.
  • 8Barbacid M. The ras oncogene. Annu Rev Biochem [J], 1987,56:779-828.
  • 9Daniele M, Leonard, Judith S, et al. Ras farnesyltransferase inhibitors. Drugs Future [J], 1999,24(10):1099-1106.
  • 10Grammer RD, Patterson DE, Bunce JD. Comparative molecular field analysis (CoMFA) 1: Effect of shapeon binding of steroids to carrieer proteins. J Am Chem Soc [J], 1988,110(18):5959.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部